Viet NamTuberculosis profile
Population  2014 92 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 17 (11–23) 18 (12–25)
Mortality (HIV+TB only) 1.9 (1.3–2.5) 2 (1.4–2.7)
Prevalence  (includes HIV+TB) 180 (76–330) 198 (83–362)
Incidence  (includes HIV+TB) 130 (110–150) 140 (116–167)
Incidence (HIV+TB only) 7 (5.7–8.5) 7.6 (6.1–9.2)
         
Case detection, all forms (%) 77 (65–94)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 4 (2.5–5.4) 23 (17–30)
MDR-TB cases among notified pulmonary
TB cases
3 000 (1 900–4 100) 2 100 (1 500–2 600)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 49 938   7 114
Pulmonary, clinically diagnosed 25 179    
Extrapulmonary 18 118    
       
Total new and relapse 100 349    
Previously treated, excluding relapses 1 738    
Total cases notified 102 087    
Among 49 929 new cases:
144 (<1%) cases aged under 15 years; male:female ratio: 3.0
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 2 756 (6%) 8 511 (96%) 13 829
Laboratory-confirmed RR-/MDR-TB cases     2 198
Patients started on MDR-TB treatment ***     1 532
TB/HIV 2014 Number (%)
TB patients with known HIV status 74 092 (73)
HIV-positive TB patients 3 875 (5)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 2 936 (76)
HIV-positive TB patients on antiretroviral therapy (ART) 2 827 (73)
HIV-positive people screened for TB 90 592  
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (89) 102 196
Previously treated cases, excluding relapse, registered in 2013    
HIV-positive TB cases, all types, registered in 2013 (71) 4 453
RR-/MDR-TB cases started on second-line treatment in 2012 (71) 713
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 1.1
Culture (per 5 million population) 1.2
Drug susceptibility testing (per 5 million population) 0.1
Sites performing Xpert MTB/RIF 30
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 66
% Funded domestically 10%
% Funded internationally 17%
% Unfunded 72%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-07-23 Data: www.who.int/tb/data